The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Manickasingham, S.
Right arrow Articles by Reis e Sousa, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Manickasingham, S.
Right arrow Articles by Reis e Sousa, C.
The Journal of Immunology, 2000, 165: 5027-5034.
Copyright © 2000 by The American Association of Immunologists

Microbial and T Cell-Derived Stimuli Regulate Antigen Presentation by Dendritic Cells In Vivo1

Shivanthi Manickasingham and Caetano Reis e Sousa2

Immunobiology Laboratory, Imperial Cancer Research Fund, London, United Kingdom


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
B cells and dendritic cells (DC) internalize and degrade exogenous Ags and present them as peptides bound to MHC class II molecules for scrutiny by CD4+ T cells. Here we use an Ab specific for a processed form of the model Ag, hen egg lysozyme (HEL), to demonstrate that this protein is not efficiently presented by lymph node DC following s.c. immunization. HEL presentation by the DC can be dramatically enhanced upon coinjection of a microbial adjuvant, which appears to act by enhancing peptide loading onto MHC class II. CD40 cross-linking or the presence of a high frequency of T cells specific for HEL can similarly improve presentation by DC in vivo. For any of these activating stimuli, CD8{alpha}+ DC consistently display the highest proportion of HEL-loaded MHC class II molecules. These data indicate that exogenous Ags can be displayed to T cells in lymphoid tissues by a large cohort of resident DC whose presentation is regulated by innate and adaptive stimuli. Our data further reveal the existence of a feedback mechanism that augments Ag presentation during cognate APC-T cell interactions.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The activation of naive T cells requires two signals provided by accessory cells termed APCs. The first signal is delivered through the TCR upon engagement of MHC molecules loaded with the appropriate peptide. Signal 2 involves cross-linking of CD28 and other receptors on the T cell by costimulatory molecules expressed by the APC (1, 2). Many of the peptides recognized by CD4+ T cells in the context of MHC class II molecules derive from protein Ags taken up and degraded in the endocytic compartment of APC (3, 4). It has generally been assumed that the degradation of proteins and conversion to MHC class II-bound peptides occur constitutively, allowing presentation4 of any Ags that gain access to the endosomes of APC. These might include self proteins as well as Ags from infectious organisms, because the APC is unable to discriminate between peptide sources. However, immune responses are thought to be focused on Ags from infectious organisms because only the latter induce expression of costimulatory molecules on APC (5).

While B cells indeed present constitutively in vivo those Ags acquired pinocytically (6, 7), other data suggest that this may not be true of dendritic cells (DC),4 the most important APC in regulating T cell responses (8, 9, 10, 11). To examine the requirements for presentation of a foreign Ag by murine DC and B cells in vivo, we used the C4H3 mAb specific for I-Ak in association with the 46–61 fragment of the model Ag hen egg lysozyme (HEL; Ref. 12). This Ab can stain APC bearing high levels of processed HEL in vitro and in vivo, allowing direct measurement of presentation in the absence of ancillary factors that can influence T cell assays of APC function (6, 7, 12). Using this reagent, we find that although the majority of DC in lymph nodes is able to process and present HEL in vitro, it is unable to do so efficiently in vivo unless an activation stimulus is provided together with the Ag. This stimulus can take the form of a microbial adjuvant, anti-CD40, or, remarkably, the presence of Ag-specific T cells and acts to promote and sustain the presentation of a high frequency of antigenic complexes primarily by CD8{alpha}+ DC. Together, these results suggest that the ability of DC to present Ags in vivo is regulated and coupled to activation. Activation-linked presentation results in a marked increase in T cell stimulation.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Reagents

HEL, Con A, Lucifer Yellow, FITC-dextran, and LPS were purchased from Sigma (St. Louis, MO). All reagent stocks were tested for endotoxin content (Limulus amebocyte lysate assay; BioWhittaker, Walkersville, MD) and, if necessary, rigorously depleted of the contaminant by several passes through KuttsuClean (Maruha, Ibaraki, Japan), as recommended by the manufacturer. Residual levels of endotoxin in HEL were below 8 endotoxin units/mg. Repeated depletion with KuttsuClean did not decrease these levels further.

Monoclonal Abs

C4H3 is a rat IgG2b mAb that recognizes residues 46–61 of HEL in the context of I-Ak (12). All other mAbs were purchased from PharMingen (San Diego, CA). mAbs used for in vivo treatment were endotoxin-free 3/23 anti-CD40 (13) and an isotype-matched (rat IgG2a) control Ab. mAbs used for staining were 10-3.6 and MR5-2, mouse IgG2a specific for I-Ak and Vß8.1/8.2, respectively; RA3-6B2, RM4-5, and 53-6.7, rat IgG2a against B220, CD4, and CD8{alpha}, respectively; and HL3 and H1.2F3, hamster IgG against CD11c and CD69, respectively. Irrelevant isotype-matched control Abs were used to validate the specificity of staining.

Animals

Male and female B10.BR mice were obtained from Harlan U.K. (Bicester, U.K.) and were used at 6–20 wk of age. Mice were injected s.c. with HEL in the base of the tail or in the footpad for analysis of APC in surface inguinal lymph nodes or popliteal nodes, respectively. C4H3 detection of presentation in popliteal lymph nodes could be accomplished using 250–400 µg HEL administered to the footpad in 50 µl PBS. Similar detection in surface inguinal nodes required the injection of 1–4 mg HEL in 100 µl PBS. LPS or mAbs were used alone or in conjunction with HEL at the indicated doses. Control mice were injected with PBS.

Adoptive transfer

For adoptive transfer experiments, cells were taken from mice transgenic for 3A9 TCR, specific for I-Ak/HEL46–61 (14). These mice were purchased from The Jackson Laboratory (Bar Harbor, ME) on a B10.BR background and were bred at the Imperial Cancer Research Fund animal facility. Cells taken from lymph nodes and spleen were labeled with carboxymethyl fluorescein diacetate (Molecular Probes, Eugene, OR) and transferred i.v. (0.5–1 x 107 cells/mouse) into sex-matched B10.BR mice. 3A9 T cells in the recipients (0.2% of lymph node cells) were identified by flow cytometry as fluorescent cells that stained for CD4 and Vß8.2. Experiments using cells from 3A9 mice or from 3A9 mice bred into a recombinase-activating gene-2-/- B10.BR background gave identical results.

Cells

In initial experiments lymph node cell suspensions were prepared by collagenase/DNase digestion (15). However, because commercial supplies of collagenase contain substantial levels of endotoxin, in later experiments LPS-free Liberase (Roche Diagnostics, Lewes, U.K.) was substituted for collagenase. The phenotype and yield of DC obtained by either digestion method were identical (N. Rogers and C. Reis e Sousa, unpublished observations), and all the analysis reported here was unaffected by the digestion protocol.

Flow cytometry

Lymph node cells were stained with C4H3 as described for spleen (7). Briefly, half of each cell suspension was stained using unconjugated C4H3, followed by biotinylated mouse F(ab')2 anti-rat IgG (Jackson ImmunoResearch, West Grove, PA), except in experiments involving immunization with anti-CD40, in which biotinylated C4H3 was used instead. The other half of the sample was stained with biotinylated 10-3.6. All samples were then treated with a cocktail of FITC- or APC-conjugated anti-CD8{alpha}, PE-conjugated anti-CD11c, Tricolor-conjugated streptavidin (Caltag, San Francisco, CA), and FITC- or APC-conjugated anti-B220 together with an excess of unconjugated rat IgG and 2.4G2 supernatant (anti-Fc{gamma}RII/III) (16).

Two hundred thousand to 500,000 events were collected on a FACScalibur cytometer (Becton Dickinson, Mountain View, CA) and analyzed using FlowJo software (Treestar, San Carlos, CA). Live cells were selected based on TOPRO exclusion (Molecular Probes) and/or scatter profile. APC populations were defined as shown in Fig. 1GoA. Median, rather than mean, fluorescence values were determined for each parameter measured, as medians are a stricter representation of the fluorescence of the population as a whole.



View larger version (38K):
[in this window]
[in a new window]
 
FIGURE 1. B cells and DC process and present HEL with similar efficiency in vitro. Cell suspensions from lymph nodes of B10.BR mice were incubated overnight with 1 mg/ml of HEL alone, 1 µg/ml added LPS, or in medium alone. The cells were subsequently stained with anti-CD11c, anti-CD8{alpha}, anti-B220, and either C4H3 or anti-I-Ak. A, HEL presentation by CD8{alpha}- DC, CD8{alpha}+ DC, and B cells was assessed by placing gates arund the CD11c+ CD8{alpha}+ cells, CD11c+ CD8{alpha}- cells, and the CD11c- B220+ cells. The apparent skewing of CD11c+ cells toward CD8 expression is not an artifact of electronic compensation and reflects low levels of CD8{alpha} expression by the CD8{alpha}- subset. B, The histogram overlays show C4H3 or I-Ak staining on gated APC incubated with either HEL (thin line), HEL plus LPS (thick line), LPS (dashed line), or medium alone (dotted line). The median C4H3 (C) and I-Ak (D) fluorescence was calculated for each APC subpopulation and is shown as raw values. A—D, A representative experiment. E, The average of three experiments in which C4H3 values were normalized to take into account different levels of I-Ak on different APC (see Materials and Methods). Error bars represent 1 SEM. Differences between the control group and the HEL group were highly significant (p <= 0.003, by t test). Differences among APC or between HEL and HEL plus LPS groups were not statistically significant.

 
C4H3 analysis of processed Ag display by APC

Surface inguinal or popliteal lymph nodes were generally pooled from groups of two or three mice. For analysis of presentation, the median C4H3 fluorescence for each lymph node APC population was calculated and normalized by dividing this value by the corresponding I-Ak median fluorescence (7). This method takes into account differences in surface I-Ak levels among APC and any changes in these levels induced by in vitro culture or immunization (see Figs. 1Go and 4Go). The normalization procedure also reduces C4H3 values, such that presentation in normalized samples is only apparent when high levels of HEL46–61 are presented preferentially over self peptides (7).



View larger version (32K):
[in this window]
[in a new window]
 
FIGURE 4. HEL-specific T cells augment HEL presentation in vivo by B cells and CD8{alpha}+ DC. Normal B10.BR controls or 3A9 adoptive recipients were injected in the base of the tail with 4 mg of HEL with or without 1 µg LPS or PBS. Mice were sacrificed 6 h later, and APC from surface inguinal lymph nodes were analyzed for HEL presentation as before. A, C4H3 median fluorescence from a representative experiment. B, Median I-Ak fluorescence from the same experiment. C, Average of four experiments in which the data are expressed as a percentage of the normalized C4H3 fluorescence in PBS-immunized mice (dotted line). Error bars represent 1 SEM. Statistical analysis was performed using ANOVA. LPS alone or PBS plus 3A9 had no effect on the normalized staining. Both HEL plus LPS and HEL plus 3A9 gave significantly more normalized staining of CD8{alpha}+ DC than HEL alone (p = 0.001, both). No statistically significant difference between HEL and HEL plus LPS/3A9 was seen for either CD8{alpha}- DC or B cells. D, C4H3 and I-Ak staining of B cells, CD8{alpha}+ DC, and CD8{alpha}- DC from one of the experiments in C. Dotted line, PBS; thin line, HEL; thick line, HEL plus 3A9.

 
The data are displayed as a percentage of the normalized C4H3 fluorescence for control mice injected with PBS. Because the latter were used as a baseline, they were assessed more extensively. Thus, in all experiments, PBS data were obtained from six to eight pooled lymph nodes. In addition, in some experiments PBS data were averaged from three different samples using four lymph nodes per sample, which were stained, acquired, and analyzed separately by FACS, or from 12 lymph nodes, which were pooled, but then stained, acquired, and analyzed separately by FACS. Data compiled from multiple experiments are shown as the average ± SEM. Statistical analysis was conducted using t tests or ANOVA.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Lymph node B cells and DC process and present Ags in vitro with similar efficiency

The processing and presentation of HEL protein by B cells and DC subsets in vitro was assessed by staining whole lymph node cell populations with the C4H3 Ab after overnight culture in the presence of HEL. CD11c was used as a marker for DC, which were subdivided into CD8{alpha}- and CD8{alpha}+ populations (Fig. 1GoA). B cells were identified based on their expression of B220 and their lack of CD11c expression (Fig. 1GoA).

In cells cultured in medium alone, the C4H3 Ab stained a subset of I-Ak molecules loaded with certain unidentified self peptides (henceforth referred to as background staining; Fig. 1Go, B and C; Ref. 12). The level of background staining varied among APC types, but was roughly proportional to the amount of I-Ak expressed at the cell surface (Fig. 1Go, C and D). C4H3 staining of both B cells and DC increased 6- and 10-fold, respectively, after culture with HEL protein (Fig. 1Go, B and C). Surface I-Ak levels increased by 1.5- and 1.3-fold, respectively, in response to the same Ag (Fig. 1Go, B and D). Because increases in I-Ak expression could increase background staining, to take I-Ak levels into consideration, median C4H3 fluorescence values were divided by those for I-Ak (see Materials and Methods). Normalized values represent the fraction of I-Ak molecules loaded with HEL46–61 and indicate the efficiency with which the epitope is generated (7). Analyzed in this manner, HEL exposure in vitro resulted in an average increase of 3- to 4-fold in the normalized C4H3 levels of lymph node APC across multiple experiments (Fig. 1GoE). Addition of LPS did not alter the frequency of C4H3 epitopes displayed by B cells or DC in vitro (Fig. 1Go, B–E).

Virtually all B cells presented HEL, as assessed by the unimodal C4H3 staining pattern after HEL exposure (Fig. 1GoB). Surprisingly, a unimodal C4H3 staining pattern was also seen with both DC subsets (Fig. 1GoB), suggesting that the vast majority of lymph node DC were able to process native HEL in vitro. CD8{alpha}+ DC exhibited the highest absolute levels of C4H3 staining after exposure to HEL (Fig. 1Go, B and C). However, these cells also expressed the highest surface levels of I-Ak after culture (Fig. 1Go, B and D). When I-Ak levels were accounted for by normalization, both B cells and DC processed HEL in vitro with similar efficiency, as reported for spleen APC (6).

Endotoxin promotes Ag presentation by CD8{alpha}+ DC in vivo

To study HEL presentation in vivo, groups of mice were immunized s.c. in the base of the tail with HEL depleted of endotoxin. Cell suspensions were prepared from surface inguinal lymph nodes and were stained with C4H3 or anti-I-Ak. Staining data were normalized to I-Ak levels (see above) to give a measure of the proportion of I-Ak molecules loaded with HEL46–61. As shown in Fig. 2GoA, B cell presentation of HEL could be detected in draining inguinal lymph nodes as early as 3 h after HEL administration to the base of the tail. The response peaked at 6 h and declined to near background levels by 24 h postimmunization. Remarkably, there was only a slight increase in the frequency of C4H3 epitopes detected on CD8{alpha}+ or CD8{alpha}- DC during this period despite administration of doses of HEL as high as 4 mg/mouse (Fig. 2Go, B and C). Similar results were obtained in popliteal lymph nodes following footpad immunization (not shown). The failure of DC to present HEL at the same level as B cells (Fig. 2Go, A–C) was not due to lower endocytic activity, as FITC-HEL and other endocytic tracers accumulated to a greater extent in popliteal lymph node DC than in B cells after footpad injection (Table IGo). Thus, in contrast to that in vitro, DC presentation of exogenous Ags occurs inefficiently in vivo.



View larger version (26K):
[in this window]
[in a new window]
 
FIGURE 2. HEL presentation by CD8{alpha}+ DC in vivo is increased by LPS coadministration. A—C, Mice were injected at the base of the tail with 4 mg HEL alone or with HEL plus 1 µg LPS at different times to give 3, 6, and 24 h of exposure to Ag. PBS or LPS alone were used as controls (0 h). Cells from surface inguinal lymph nodes were stained and analyzed for the frequency of C4H3 epitopes. The normalized data are shown as a percentage of the values in PBS-treated mice. In multiple experiments, injection of LPS alone did not increase the normalized C4H3 fluorescence at any time point despite causing an increase in DC MHC class II levels (not shown). D, C4H3 and I-Ak staining of CD8{alpha}+ and CD8{alpha}- DC in popliteal nodes from mice immunized 24 h previously in the footpad with PBS (dotted line), 50 ng LPS (dashed line), 250 µg HEL alone (thin line), or HEL plus LPS (thick line). E, Similar to D, except that the mice were injected with 50 µg HEL46–61 peptide with or without 50 ng LPS. Data are plotted as a percentage of the normalized C4H3 staining value obtained in PBS-injected mice (dotted line). The data are representative of three experiments for A–C, four experiments for D, and two experiments for E.

 

View this table:
[in this window]
[in a new window]
 
Table I. Endocytic accumulation of fluorescent tracers by lymph node APC after immunization1

 
To examine whether infectious signals could improve DC presentation, LPS was added to the HEL inoculum. LPS did not augment the frequency of HEL-loaded I-Ak molecules presented by CD8{alpha}- DC or B cells and actually decreased it in some experiments (Fig. 2Go, A and C). However, the addition of LPS to the HEL inoculum invariably caused a rapid and sustained increase in the frequency of C4H3 epitopes on CD8{alpha}+ DC compared with HEL or LPS alone (Figs. 2GoB and 4). Similar results were obtained in popliteal lymph nodes after immunization into the footpad with lower doses of HEL (Fig. 2GoD). Importantly, the overall increase in C4H3 staining (Fig. 2Go, B and D, and Fig. 4Go) induced by LPS was not due to an influx of a few CD8{alpha}+ DC expressing high levels of C4H3. Rather, the unimodal C4H3 staining pattern obtained (Fig. 2GoD) suggests that essentially all lymph node CD8{alpha}+ DC were able to process and present HEL in vivo after coadministration of LPS. In contrast, C4H3 staining of CD8{alpha}- DC increased only slightly after HEL immunization, even in the presence of LPS (Fig. 2Go, C and D). CD8{alpha}- DC also displayed higher background levels of C4H3 staining than the CD8{alpha}+ subset, consistent with greater surface expression of I-Ak (Fig. 2GoD, PBS control).

LPS coadministration did not increase the retention of endocytic tracers by lymph node APC (Table IGo), suggesting that LPS was not simply promoting Ag uptake. To address whether LPS increased HEL processing, we examined whether it could similarly promote presentation of preprocessed Ag. Low levels of C4H3 staining above background were seen on CD8{alpha}- DC, but not on CD8{alpha}+ DC, after immunization with the synthetic HEL46–61 peptide in the absence of LPS (Fig. 2GoE). LPS coadministration increased the frequency of C4H3 epitopes generated by the HEL peptide in CD8{alpha}+ DC, but had no effect on CD8{alpha}- DC (Fig. 2GoE). Thus, LPS activation acts at least in part by improving peptide loading by CD8{alpha}+ DC in vivo.

CD40 cross-linking in vivo increases HEL presentation by B cells and CD8{alpha}+ DC

To determine whether there were other stimuli that could similarly activate DC and improve processing and presentation of exogenous Ags, we examined the effect of CD40 ligation on HEL presentation. CD40 cross-linking has been shown to potently modulate the activity of DC (17). The frequency of C4H3 epitopes on CD8{alpha}+ DC in popliteal nodes was greatly enhanced and sustained when HEL was administered to the footpads in conjunction with an agonistic anti-CD40, but not a control, Ab (Fig. 3GoB). Interestingly, a similar picture was seen for B cells, suggesting that although not responsive to innate stimuli such as LPS, these APC can up-regulate Ag presentation in response to certain signals (Fig. 3GoA). As with LPS, anti-CD40 mAb did not increase the proportion of C4H3 epitopes on CD8{alpha}- DC (Fig. 3GoC).



View larger version (19K):
[in this window]
[in a new window]
 
FIGURE 3. HEL presentation by B cells and CD8{alpha}+ DC is increased by CD40 ligation. Mice were injected in the footpad at different times with HEL (400 µg/mouse) or HEL in combination with anti-CD40 or an isotype-matched control rat IgG2a Ab (both at 25 µg/mouse). Popliteal lymph node cells were analyzed as described in Fig. 1Go, A–C. Times indicate the total length of exposure to the Ag in vivo; 0 h is the PBS-injected control. The data are representative of three experiments.

 
T cells specific for HEL46–61 up-regulate HEL presentation in vivo

The effects of anti-CD40 in vivo suggested that Ag presentation by DC might be increased by molecules displayed by T cells during activation, which could ligate counter-receptors on DC such as CD40 or TNF-related activation-induced cytokine receptor. To investigate whether this occurs physiologically, we adoptively transferred cells from 3A9 TCR transgenic mice (containing T cells specific for HEL46–61 and I-Ak) into syngeneic unirradiated recipients. Twenty-four hours later the adoptive recipients were immunized with HEL or PBS. As before, immunization of normal B10.BR controls with HEL alone increased C4H3 staining primarily on B cells, while the addition of LPS to the inoculum (positive control) specifically augmented C4H3 staining on CD8{alpha}+ DC (Fig. 4GoA). This increase was disproportionate to any increase in I-Ak levels (Fig. 4GoB) and was best illustrated by the increase in the average normalized C4H3 fluorescence from multiple experiments (Fig. 4GoC). Interestingly, in 3A9 adoptive recipients HEL alone similarly resulted in an increase in C4H3 staining of CD8{alpha}+ DC, reaching the level obtained in control mice immunized with HEL and LPS (Fig. 4Go, A and D). Again, the increase in C4H3 fluorescence was out of proportion to any change in I-Ak expression (Fig. 4Go, B and D). Across multiple experiments this was reflected in a marked increase in the normalized C4H3 value, as shown in Fig. 4GoC. All the transgenic T cells in HEL-immunized mice, but not in PBS-injected controls, up-regulated CD69, indicating that they had become activated (not shown). This suggests that T cell recognition of cognate Ag initiates a feedback mechanism that results in increased Ag display by some APC.

Increased HEL presentation after adjuvant coadministration results in increased T cell activation

The above results suggested that innate and adaptive signals that increase DC activation can markedly enhance Ag presentation, i.e., the delivery of signal 1 to T cells. However, experiments using the C4H3 Ab to detect presentation in vivo require the administration of doses of HEL far in excess of those required to activate HEL-specific T cells. To extrapolate our findings to physiologically relevant Ag doses, we measured the activation of 3A9 T cells in vivo in response to HEL alone or HEL plus LPS. We used doses of Ag that allow formation of enough antigenic complexes to activate T cells but do not result in a detectable increase in C4H3 binding. Although 3A9 T cells up-regulated CD69 in response to immunization with HEL alone, 100-fold higher Ag doses were required to approach the levels of CD69 seen in response to HEL plus LPS (Fig. 5GoA). This result demonstrates that the microbial signal acts as a potent adjuvant to promote T cell activation. To determine whether this was due to increased Ag presentation or simply to up-regulation of costimulatory and/or adhesion molecules after LPS treatment, we measured CD69 up-regulation on 3A9 T cells in mice immunized with Con A, an Ag that is independent of MHC presentation but that still depends on other APC-derived signals for T cell activation. In contrast to its effects on the 3A9 response to HEL, LPS only slightly increased the activation of 3A9 T cells in response to Con A (Fig. 5GoB). Therefore, the addition of LPS to HEL augments 3A9 activation largely by increasing delivery of signal 1 to T cells rather than costimulatory or other signals.



View larger version (20K):
[in this window]
[in a new window]
 
FIGURE 5. LPS increases activation of 3A9 T cells in response to HEL. 3A9 adoptive recipients were injected in the footpad with the indicated doses of HEL or Con A with or without 50 ng LPS. Mice were sacrificed 18 h later, and popliteal nodes were stained for CD4, Vß8.2, and CD69. The data are the median CD69 expression on donor 3A9 T cells (carboxymethyl fluorescein diacetate (CMFDA)+, CD4+, Vß8.2+) and are representative of two experiments. Median fluorescence values for the zero Ag dose were: no LPS, 2.7; and LPS, 8.1.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
DC and B cells isolated from rodents injected or fed with foreign proteins can be used to activate Ag-specific MHC class II-restricted T cells in vitro (6, 18, 19, 20, 21, 22, 23). For this reason, it has generally been assumed that any Ag will be presented by all those APC that have access to it in vivo. In this model, uptake by an APC that is capable of processing and presenting is the critical parameter that determines the ability of a given Ag to be encountered by T cells. Here, we report that although this model may be largely correct for Ag presentation by B cells, it is not generally applicable to DC presentation in vivo. Thus, we find that although DC internalize Ags by fluid phase endocytosis, they do not constitutively present them at high levels in lymph nodes. Presentation of a high frequency of antigenic epitopes is induced by coadministration of an activation stimulus, which can be of microbial or T cell origin. These stimuli do not augment Ag uptake (Table IGo), but improve Ag loading onto MHC class II molecules (Fig. 2GoE). Although it remains possible that lymph node DC process exogenous Ags exclusively by an extracellular pathway (24), our results are consistent with the idea that the MHC class II groove in immature DC is occupied by invariant chain, which cannot be degraded until the cells receive an activation signal (10, 11).

Because of the exquisite susceptibility of DC to activation by microbes (25), coupling of Ag presentation to DC activation may, therefore, bias DC to present Ags of microbial origin rather than self proteins. This idea fits the proposal that innate recognition of infectious organisms initiates adaptive immunity (5, 26, 27), but extends it to suggest that exposure to microbial stimuli leads not only to up-regulation of costimulatory molecules on APC and consequent increased delivery of signal 2 to T cells (28), but also up-regulation of Ag presentation and increased delivery of signal 1. This has important implications for our understanding of immune function and for vaccine design, because it implies that adjuvants act in part by promoting the formation and display of antigenic complexes by DC. In concert with increases in costimulation and cytokine production, this may facilitate and sustain T cell activation, clonal expansion, and generation of memory cells (29).

In our analysis, C4H3 staining was normalized to the staining obtained with an Ab against I-Ak (see Materials and Methods). Normalization is necessary because C4H3 cross-reacts with a subset of I-Ak molecules loaded with certain self-peptides (7, 12). Any increase in total MHC class II levels is likely to increase this background proportionately. An example of this can be seen after immunization with LPS alone, which causes an increase in the absolute C4H3 (Fig. 4GoA) and I-Ak (Fig. 4GoB) staining of DC, but fails to affect the normalized C4H3 value (Fig. 4GoC). However, normalization may well underestimate the amount of HEL presentation in our experiments. It has previously been shown that the presence of high concentrations of HEL protein can lead to increased surface I-Ak expression by B cells through rescue of molecules that would otherwise be targeted for lysosomal degradation because of failure to be loaded with peptide (30, 31). Such rescue is consistent with the increase in I-Ak levels seen after incubation of lymph node cells with HEL in vitro (Fig. 1Go, B and D). In these circumstances, normalization penalizes cells that up-regulate I-Ak because of HEL loading and effectively biases the analysis toward those APC presenting the highest levels of HEL.

The fact that normalized data represent proportion, rather than total number, of HEL-loaded I-Ak molecules should be borne in mind when thinking of the implications of our data for T cell recognition. For example, although the proportion of HEL-loaded I-Ak molecules on CD8{alpha}- DC is lower than that on CD8{alpha}+ DC after immunization (Figs. 2Go and 4Go), the fact that the former APC express higher absolute levels of I-Ak (Fig. 4Go, B and D) may result in equivalent or higher absolute levels of HEL-loaded MHC class II. It is not clear at this stage whether T cell recognition depends only on the absolute levels of Ag display on APC or is sensitive to the frequency of MHC molecules loaded with the antigenic peptide. In support of the latter, self-peptide-loaded MHC complexes can act as TCR antagonists (32, 33), and a high frequency of antigenic complexes on APC has been associated with increased priming of CD8+ T cells (34, 35, 36, 37). Although we believe that normalization is essential for understanding our results, we also include raw median fluorescence values and FACS profiles in Figs. 1Go, 2Go, and 4Go, which give an indication of the magnitude of the changes in the actual data and may show a different hierarchy of presentation by DC subsets.

In contrast to its effect in vivo, LPS did not increase HEL processing and presentation by either DC subset in vitro (Fig. 1Go, B–E). This suggests that simply disrupting the tissue and culturing lymph node cells provide signals analogous to those provided by LPS in vivo, which result in a marked increase in DC presentation. Such signals are not present in cultures of bone marrow-derived DC, which remain relatively quiescent and unable to present HEL until activated by LPS or CD40 ligation (11). The activation of DC upon isolation from tissues is a well-known feature (38) and may also explain the differences in surface MHC class II levels between DC subsets seen before and after culture. Thus, freshly isolated CD8{alpha}+ DC express lower surface levels of MHC class II than CD8{alpha}- DC (Fig. 4Go, B and D), but up-regulate it to a greater degree in culture (Fig. 1Go, B and D), in part due to redistribution of MHC molecules sequestered in intracellular compartments (N. Rogers and C. Reis e Sousa, unpublished observations). Interestingly, intracellular sequestration of MHC class II and expression of invariant chain and cystatin C are more prevalent in resting CD8{alpha}+ DC than in CD8{alpha}- DC (N. Rogers, O. Schulz, and C. Reis e Sousa, unpublished observations), consistent with the ability of the former subset to rapidly load a high frequency of I-Ak molecules with HEL peptides upon activation in vivo.

Although lymph node CD8{alpha}- DC did not display a high frequency of C4H3 epitopes in our immunization experiments ( Figs. 2–4GoGoGo), they did so after in vitro culture with the Ag (Fig. 1Go). This result suggests that the CD8{alpha}- DC subset is capable of efficient Ag processing, but that as yet unidentified signals are required to induce high levels of presentation in vivo. Such stimuli may include endogenous signals such as recognition of dying cells (39, 40, 41, 42). Endogenous signals may also explain the low level HEL presentation by DC in the absence of added adjuvants ( Figs. 2–4GoGoGo), which appears to be independent of residual endotoxin in the Ag preparation (our unpublished observations). Given a likely role for DC in cross-tolerance to tissue Ags (43), it is interesting to speculate that some signals may induce DC presentation without causing up-regulation of costimulatory molecules.

Interestingly, presentation of LPS-free HEL by CD8{alpha}+ DC can be detected if the mouse has previously received transgenic naive T cells specific for the Ag (Fig. 4Go). How can a T cell provide signals that initiate presentation of Ags by DC if those signals depend on recognizing Ag in the first place? In other work, we have found that T cell feedback amplifies cytokine production by DC in vivo, but this is dependent upon prior DC activation by innate signals (48). It is likely, therefore, that T cells do not initiate Ag presentation, but simply augment it by "rewarding" APC expressing small amounts of the right peptide:MHC complexes. HEL in the absence of added LPS can still be presented by B cells and also by DC at low levels (Figs. 2Go and 4Go), which may be sufficient to initiate T cell activation. However, a positive feedback loop would dramatically increase the responsiveness of naive T cells to low amounts of Ag during initial T cell activation (Fig. 5Go). Amplification of presentation could also, perhaps, allow recruitment of lower affinity T cells into the priming reaction, effectively leading to clonal diversification. Positive feedback may be mediated in part through CD40 cross-linking on the APC by CD40 ligand (CD40L) up-regulated on the T cell, consistent with the effects of anti-CD40 Ab on presentation. However, blocking studies with anti-CD40L Ab to address this issue proved inconclusive. A maximum inhibition of 20% of the increase in normalized C4H3 staining of DC was seen after CD40L blockade in 3A9 adoptive recipients (data not shown). This may indicate our inability to achieve full blockade or, more likely, may reflect the presence of additional T cell ligands for CD40 and/or the effect of related molecules such as TNF-related activation-induced cytokine (44, 45). Studies are underway to determine the relative contribution to DC activation of DC receptors for T cell signals.

Langerhans cells freshly isolated from skin and exposed to intact protein Ags in vitro can generate antigenic complexes that activate Ag-specific, MHC class II-restricted T cells. However, they rapidly lose the ability to do so upon culture, a phenomenon termed maturation (46), which in vivo is thought to be accompanied by migration of Langerhans cells to the T cell areas of draining lymph nodes (38, 47). This has often been interpreted to mean that DC in secondary lymphoid tissues are the end product of the maturation process. Surprisingly, we find that most freshly isolated lymph node DC of either subset are capable of processing and presenting native Ag in vitro and that, given the appropriate stimulus, CD8{alpha}+ DC can do so in vivo. Thus, our data indicate that the great majority of DC in lymph nodes are immature cells capable of endocytosing Ags that drain to those sites and able to process and present them at high levels upon receiving an appropriate stimulus. Similarly, the majority of splenic DC can process and present native HEL protein (6). One may, therefore, envisage two mechanisms for Ag presentation in the T cell areas of secondary lymphoid tissues. One involves the conventional pathway of immigration into the tissue of DC originally present at the site of antigenic challenge. Another involves a large cohort of resident immature lymph node DC, which permanently sample lymph or blood contents and up-regulate presentation in response to the presence of inflammatory mediators draining from sites of infection. Some of these DC may also be capable of phagocytosing incoming tissue DC and represent the Ags they transported, as recently suggested (40). The existence of multiple mechanisms for Ag presentation in secondary lymphoid tissues might exist to ensure amplification of a nascent response by maximizing the number of DC presenting relevant Ags and allowing efficient selection of T lymphocytes with the appropriate Ag specificity.


    Acknowledgments
 
We thank Stephanie Vogel for the suggestion to use KuttsuClean, and Doreen Cantrell, Mike Owen, and members of the Immunobiology Laboratory for helpful discussions and for reading the manuscript. We are grateful to Gill Hutchinson and Julie Bee for their expert assistance and animal care, and to Mike Bradburn of the Imperial Cancer Research Fund Medical Statistics Group for statistical analysis.


    Footnotes
 
1 This work was supported by the Imperial Cancer Research Fund. Back

2 Address correspondence and reprint requests to Dr. Caetano Reis e Sousa, Immunobiology Laboratory, Imperial Cancer Research Fund, 44 Lincoln’s Inn Fields, Holborn, London, WC2A 3PX U.K. Back

3 Abbreviations used in this paper: DC, dendritic cells; HEL, hen egg lysozyme; CD40L, CD40 ligand. Back

4 Ag presentation in this paper is used strictly to denote the display by APC, at the cell surface, of MHC molecules loaded with peptides from the Ag in question. Back

Received for publication May 8, 2000. Accepted for publication August 10, 2000.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Mondino, A., A. Khoruts, M. K. Jenkins. 1996. The anatomy of T-cell activation and tolerance. Proc. Natl. Acad. Sci. USA 93:2245.[Abstract/Free Full Text]
  2. Lenschow, D. J., T. L. Walunas, J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:233.[Medline]
  3. Germain, R. N.. 1994. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76:287.[Medline]
  4. Cresswell, P.. 1994. Assembly, transport, and function of MHC class II molecules. Annu. Rev. Immunol. 12:259.[Medline]
  5. Jr Janeway, C. A.. 1989. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54:1.
  6. Zhong, G., C. Reis e Sousa, R. N. Germain. 1997. Antigen-unspecific B cells and lymphoid dendritic cells both show extensive surface expression of processed antigen:MHC class II complexes after soluble protein exposure in vivo or in vitro. J. Exp. Med. 186:673.[Abstract/Free Full Text]
  7. Reis e Sousa, C., R. N. Germain. 1999. Analysis of adjuvant function by direct visualization of antigen presentation in vivo: endotoxin promotes accumulation of antigen-bearing dendritic cells in the T cell areas of lymphoid tissue. J. Immunol. 162:6552.[Abstract/Free Full Text]
  8. Cella, M., A. Engering, V. Pinet, J. Pieters, A. Lanzavecchia. 1997. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388:782.[Medline]
  9. Pierre, P., S. J. Turley, E. Gatti, M. Hull, J. Meltzer, A. Mirza, K. Inaba, R. M. Steinman, I. Mellman. 1997. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 388:787.[Medline]
  10. Pierre, P., I. Mellman. 1998. Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells. Cell 93:1135.[Medline]
  11. Inaba, K., S. Turley, T. Iyoda, F. Yamaide, S. Shimoyama, C. Reis e Sousa, R. N. Germain, I. Mellman, R. M. Steinman. 2000. The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J. Exp. Med. 191:927.[Abstract/Free Full Text]
  12. Zhong, G., C. Reis e Sousa, R. N. Germain. 1997. Production, specificity, and functionality of monoclonal antibodies to specific peptide:MHC class II complexes formed by processing of exogenous protein. Proc. Natl. Acad. Sci. USA 94:13856.[Abstract/Free Full Text]
  13. Hasbold, J., C. Johnson-Leger, C. J. Atkins, E. A. Clark, G. G. Klaus. 1994. Properties of mouse CD40: cellular distribution of CD40 and B cell activation by monoclonal anti-mouse CD40 antibodies. Eur. J. Immunol. 24:1835.[Medline]
  14. Ho, W. Y., M. P. Cooke, C. C. Goodnow, M. M. Davis. 1994. Resting and anergic B cells are defective in CD28-dependent costimulation of naive CD4+ T cells. J. Exp. Med. 179:1539.[Abstract/Free Full Text]
  15. Swiggard, W., R. M. Nonacs, M. D. Witmer-Pack, and R. M. Steinman. 1991. Enrichment of dendritic cells by plastic adherence and EA rosetting. In Current Protocols in Immunology. J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober, eds. John Wiley & Sons, New York, pp. 3.7.1–3.7.11.
  16. Unkeless, J. C.. 1979. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J. Exp. Med. 150:580.[Abstract/Free Full Text]
  17. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. Pulendran, K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767.[Medline]
  18. Kyewski, B., C. Fathman, R. Rouse. 1986. Intrathymic presentation of circulating non-MHC antigens by medullary dendritic cells: an antigen-dependent microenvironment for T cell differentiation. J. Exp. Med. 163:231.[Abstract/Free Full Text]
  19. Crowley, M., K. Inaba, R. M. Steinman. 1990. Dendritic cells are the principal cells in mouse spleen bearing immunogenic fragments of foreign proteins. J. Exp. Med. 172:383.[Abstract/Free Full Text]
  20. Liu, L. M., G. G. MacPherson. 1993. Antigen acquisition by dendritic cells: intestinal dendritic cells acquire antigen administered orally and can prime naive T cells in vivo. J. Exp. Med. 177:1299.[Abstract/Free Full Text]
  21. Constant, S., N. Schweitzer, J. West, P. Ranney, K. Bottomly. 1995. B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. J. Immunol. 155:3734.[Abstract]
  22. Guéry, J. C., F. Ria, L. Adorini. 1996. Dendritic cells but not B cells present antigenic complexes to class II-restricted T cells after administration of protein in adjuvant. J. Exp. Med. 183:751.[Abstract/Free Full Text]
  23. Guéry, J. C., F. Ria, F. Galbiati, S. Smiroldo, L. Adorini. 1997. The mode of protein antigen administration determines preferential presentation of peptide-class II complexes by lymph node dendritic or B cells. Int. Immunol. 9:9.[Abstract/Free Full Text]
  24. Santambrogio, L., A. K. Sato, G. J. Carven, S. L. Belyanskaya, J. L. Strominger, L. J. Stern. 1999. Extracellular antigen processing and presentation by immature dendritic cells. Proc. Natl. Acad. Sci. USA 96:15056.[Abstract/Free Full Text]
  25. Reis e Sousa, C., A. Sher, P. Kaye. 1999. The role of dendritic cells in the induction and regulation of immunity to microbial infection. Curr. Opin. Immunol. 11:392.[Medline]
  26. Jr Janeway, C. A.. 1992. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today 13:11.[Medline]
  27. Fearon, D. T., R. M. Locksley. 1996. The instructive role of innate immunity in the acquired immune response. Science 272:50.[Abstract]
  28. Liu, Y., C. J. Janeway. 1991. Microbial induction of co-stimulatory activity for CD4 T-cell growth. Int. Immunol. 3:323.[Abstract/Free Full Text]
  29. Kearney, E. R., K. A. Pape, D. Y. Loh, M. K. Jenkins. 1994. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1:327.[Medline]
  30. Germain, R. N., L. R. Hendrix. 1991. MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding. Nature 353:134.[Medline]
  31. Germain, R. N., Jr A. Rinker. 1993. Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes surface expression of occupied molecules. Nature 363:725.[Medline]
  32. Basu, D., C. B. Williams, P. M. Allen. 1998. In vivo antagonism of a T cell response by an endogenously expressed ligand. Proc. Natl. Acad. Sci. USA 95:14332.[Abstract/Free Full Text]
  33. Kersh, E. N., G. J. Kersh, P. M. Allen. 1999. Partially phosphorylated T cell receptor {zeta} molecules can inhibit T cell activation. J. Exp. Med. 190:1627.[Abstract/Free Full Text]
  34. De Bruijn, M. L. H., T. N. M. Schumacher, J. D. Nieland, H. L. Ploegh, W. M. Kast, C. J. M. Melief. 1991. Peptide loading of major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses. Eur. J. Immunol. 21:2963.[Medline]
  35. De Bruijn, M., J. D. Nieland, T. N. Schumacher, H. L. Ploegh, W. M. Kast, C. J. Melief. 1992. Mechanisms of induction of primary virus-specific cytotoxic T lymphocyte responses. Eur. J. Immunol. 22:3013.[Medline]
  36. Wong, C., M. Morse, S. K. Nair. 1998. Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides. J. Immunother. 21:32.
  37. Nair, S. K., D. Snyder, E. Gilboa. 1996. Cells treated with TAP-2 antisense oligonucleotides are potent antigen- presenting cells in vitro and in vivo. J. Immunol. 156:1772.[Abstract]
  38. Steinman, R. M.. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271.[Medline]
  39. Matzinger, P.. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:991.[Medline]
  40. Inaba, K., S. Turley, F. Yamaide, T. Iyoda, K. Mahnke, M. Inaba, M. Pack, M. Subklewe, B. Sauter, D. Sheff, et al 1998. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J. Exp. Med. 188:2163.[Abstract/Free Full Text]
  41. Gallucci, S., M. Lolkema, P. Matzinger. 1999. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5:1249.[Medline]
  42. Sauter, B., M. L. Albert, L. Francisco, M. Larsson, S. Somersan, N. Bhardwaj. 2000. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191:423.[Abstract/Free Full Text]
  43. Heath, W. R., C. Kurts, J. F. Miller, F. R. Carbone. 1998. Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens. J. Exp. Med. 187:1549.[Free Full Text]
  44. Josien, R., B. R. Wong, H. L. Li, R. M. Steinman, Y. Choi. 1999. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J. Immunol. 162:2562.[Abstract/Free Full Text]
  45. Bachmann, M. F., B. R. Wong, R. Josien, R. M. Steinman, A. Oxenius, Y. Choi. 1999. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J. Exp. Med. 189:1025.[Abstract/Free Full Text]
  46. Romani, N., S. Koide, M. Crowley, P. M. Witmer, A. M. Livingstone, C. G. Fathman, K. Inaba, R. M. Steinman. 1989. Presentation of exogenous protein antigens by dendritic cells to T cell clones: intact protein is presented best by immature, epidermal Langerhans cells. J. Exp. Med. 169:1169.[Abstract/Free Full Text]
  47. Austyn, J. M., C. P. Larsen. 1990. Migration patterns of dendritic leukocytes: implications for transplantation. Transplantation 49:1.[Medline]
  48. Schulz, O., A. D. Edwards, M. Schito, J. Aliberti, S. Manickasingham, A. Sher, and C. Reis e Sousa. 2000. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivorequires a microbial priming signal. Immunity. In press.



This article has been cited by other articles:


Home page
J. Immunol.Home page
F. A. Marshall and E. J. Pearce
Uncoupling of Induced Protein Processing from Maturation in Dendritic Cells Exposed to a Highly Antigenic Preparation from a Helminth Parasite
J. Immunol., December 1, 2008; 181(11): 7562 - 7570.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. J. Singh, M. Cox, and R. H. Schwartz
TLR Ligands Differentially Modulate T Cell Responses to Acute and Chronic Antigen Presentation
J. Immunol., December 15, 2007; 179(12): 7999 - 8008.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. J. Young, N. S. Wilson, P. Schnorrer, A. Mount, R. J. Lundie, N. L. La Gruta, B. S. Crabb, G. T. Belz, W. R. Heath, and J. A. Villadangos
Dendritic cell preactivation impairs MHC class II presentation of vaccines and endogenous viral antigens
PNAS, November 6, 2007; 104(45): 17753 - 17758.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
F. Odoardi, N. Kawakami, Z. Li, C. Cordiglieri, K. Streyl, M. Nosov, W. E. F. Klinkert, J. W. Ellwart, J. Bauer, H. Lassmann, et al.
Instant effect of soluble antigen on effector T cells in peripheral immune organs during immunotherapy of autoimmune encephalomyelitis
PNAS, January 16, 2007; 104(3): 920 - 925.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
H. Donaghy, J. Wilkinson, and A. L. Cunningham
HIV interactions with dendritic cells: has our focus been too narrow?
J. Leukoc. Biol., November 1, 2006; 80(5): 1001 - 1012.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
G. W. Stone, S. Barzee, V. Snarsky, K. Kee, C. A. Spina, X.-F. Yu, and R. S. Kornbluth
Multimeric Soluble CD40 Ligand and GITR Ligand as Adjuvants for Human Immunodeficiency Virus DNA Vaccines
J. Virol., February 15, 2006; 80(4): 1762 - 1772.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
G. T. Belz, C. M. Smith, L. Kleinert, P. Reading, A. Brooks, K. Shortman, F. R. Carbone, and W. R. Heath
Distinct migrating and nonmigrating dendritic cell populations are involved in MHC class I-restricted antigen presentation after lung infection with virus
PNAS, June 8, 2004; 101(23): 8670 - 8675.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
A. Engering, S. J. van Vliet, K. Hebeda, D. G. Jackson, R. Prevo, S. K. Singh, T. B. H. Geijtenbeek, H. van Krieken, and Y. van Kooyk
Dynamic Populations of Dendritic Cell-Specific ICAM-3 Grabbing Nonintegrin-Positive Immature Dendritic Cells and Liver/Lymph Node-Specific ICAM-3 Grabbing Nonintegrin-Positive Endothelial Cells in the Outer Zones of the Paracortex of Human Lymph Nodes
Am. J. Pathol., May 1, 2004; 164(5): 1587 - 1595.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Sporri and C. Reis e Sousa
Newly Activated T Cells Promote Maturation of Bystander Dendritic Cells but Not IL-12 Production
J. Immunol., December 15, 2003; 171(12): 6406 - 6413.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
D. Frleta, R. J. Noelle, and W. F. Wade
CD40-mediated up-regulation of Toll-like receptor 4-MD2 complex on the surface of murine dendritic cells
J. Leukoc. Biol., December 1, 2003; 74(6): 1064 - 1073.
[Abstract] [Full Text]


Home page
JEMHome page
S.-i. Fujii, K. Shimizu, C. Smith, L. Bonifaz, and R. M. Steinman
Activation of Natural Killer T Cells by {alpha}-Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein
J. Exp. Med., July 21, 2003; 198(2): 267 - 279.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. E. Buhlmann, S. K. Elkin, and A. H. Sharpe
A Role for the B7-1/B7-2:CD28/CTLA-4 Pathway During Negative Selection
J. Immunol., June 1, 2003; 170(11): 5421 - 5428.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
S. Fillatreau and D. Gray
T Cell Accumulation in B Cell Follicles Is Regulated by Dendritic Cells and Is Independent of B Cell Activation
J. Exp. Med., January 20, 2003; 197(2): 195 - 206.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. Muraille, C. De Trez, B. Pajak, M. Brait, J. Urbain, and O. Leo
T Cell-Dependent Maturation of Dendritic Cells in Response to Bacterial Superantigens
J. Immunol., May 1, 2002; 168(9): 4352 - 4360.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. A. Williams, S. O. Sharrow, A. J. Adams, and R. J. Hodes
CD40 Ligand Functions Non-Cell Autonomously to Promote Deletion of Self-Reactive Thymocytes
J. Immunol., March 15, 2002; 168(6): 2759 - 2765.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
I. H. Frazer, R. D. Kluyver, G. R. Leggatt, H. Yang Guo, L. Dunn, O. White, C. Harris, A. Liem, and P. Lambert
Tolerance or Immunity to a Tumor Antigen Expressed in Somatic Cells Can Be Determined by Systemic Proinflammatory Signals at the Time of First Antigen Exposure
J. Immunol., December 1, 2001; 167(11): 6180 - 6187.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Manickasingham, S.
Right arrow Articles by Reis e Sousa, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Manickasingham, S.
Right arrow Articles by Reis e Sousa, C.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS